14 completed, 5 withdrawn, 3 terminated, 1 recruiting. 6 Phase 1, 4 Not applicable, 3 Early Phase 1, 3 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 3, Withdrawn 3 |
| Not applicable | 4 | Completed 3, Terminated 1 |
| Early Phase 1 | 3 | Completed 2, Withdrawn 1 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Phase 3 | 2 | Completed 2 |
Follow Stage IIIB Ovarian Cancer: new trials by email Literature Review of Stage IIIB Ovarian Cancer trials Research Report on Stage IIIB Ovarian Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PET Imaging of Ovarian Carcinoma With 18F-FSPG (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG), Positron Emission Tomography, Laboratory Biomarker Analysis - Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer | Early Phase 1 | Withdrawn | Vanderbilt-Ingram Cancer Center | 2018-06-01 | 2018-06-06 | |
| Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Laboratory Biomarker Analysis, Recombinant NY-ESO-1 Protein, Sirolimus - Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2017-12-08 | 2018-05-01 | |
| Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer Diagnostic Microscopy, Fluorescein Sodium Injection, Laboratory Biomarker Analysis - Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma | Early Phase 1 | Completed | Roswell Park Cancer Institute | 19 | 2017-11-06 | 2021-10-06 |
| Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer Best Practice, Laboratory Biomarker Analysis, Supportive Care - Acute Myeloid Leukemia, Brain Glioblastoma | Not applicable | Completed | Stanford University | 128 | 2017-08-08 | 2025-01-24 |
| IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery Carboplatin, Gynecological Surgical Procedure, Laboratory Biomarker Analysis - Stage III Fallopian Tube Cancer, Stage III Ovarian Cancer | Phase 2 | Terminated | University of Washington | 11 | 2017-04-03 | 2022-01-14 |
| Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib - Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2016-06-01 | 2017-04-24 | |
| Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Laboratory Biomarker Analysis, Nanoparticle Albumin-Bound Rapamycin, Quality-of-Life Assessment - Advanced Malignant Neoplasm, Cervical Squamous Cell Carcinoma | Early Phase 1 | Completed | Mayo Clinic | 2 | 2016-01-01 | 2019-06-06 |
| Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer Survivors Informational Intervention - Stage I Breast Cancer, Stage I Cervical Cancer | Not applicable | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 40 | 2015-08-01 | 2025-04-29 |
| Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent Aldesleukin, HER2Bi-Armed Activated T Cells, Laboratory Biomarker Analysis - Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Serous Tumor | Phase 1 | Withdrawn | Barbara Ann Karmanos Cancer Institute | 2015-06-01 | 2016-02-17 | |
| Taking Care of Her Program in Patients With Stage III or IV Ovarian Cancer and Spouse Caregivers Telephone-Based Intervention, Caregiver-Assisted Training, Questionnaire Administration - Caregiver, Stage IIIA Ovarian Cancer | Not applicable | Completed | University of Washington | 14 | 2015-04-01 | 2017-03-07 |
| Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Cyclophosphamide, Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha Peptide Vaccine - Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma | Phase 1 | Completed | Mayo Clinic | 24 | 2012-07-24 | 2024-08-21 |
| Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study - Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma | Phase 1 | Completed | Roswell Park Cancer Institute | 18 | 2012-03-01 | 2016-10-04 |
| Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer Adjuvant Therapy, Aprepitant, Carboplatin - Nausea and Vomiting, Ovarian Brenner Tumor | Not applicable | Terminated | Gynecologic Oncology Group | 4 | 2011-06-01 | 2018-05-22 |
| OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission Laboratory Biomarker Analysis, Polyvalent Antigen-KLH Conjugate Vaccine, Saponin-based Immunoadjuvant OBI-821 - Stage IA Fallopian Tube Cancer, Stage IA Ovarian Cancer | Phase 2 | Completed | Gynecologic Oncology Group | 171 | 2010-07-01 | 2017-09-13 |
| Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Gamma-Secretase Inhibitor RO4929097, Cediranib Maleate, Pharmacological Study - Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma | Phase 1 | Completed | National Cancer Institute (NCI) | 20 | 2010-05-01 | 2014-12-23 |
| Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Cognitive Assessment, Quality-of-Life Assessment - Cognitive Side Effects of Cancer Therapy, Malignant Ovarian Epithelial Tumor | Completed | Gynecologic Oncology Group | 247 | 2010-04-01 | 2018-04-12 | |
| Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer Carboplatin, Glutathione, Laboratory Biomarker Analysis - Chemotherapeutic Agent Toxicity, Neuropathy | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 195 | 2009-12-01 | 2017-02-23 |
| Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Bevacizumab, Temsirolimus - Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 252 | 2009-09-08 | 2019-01-25 |
| YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis - Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Terminated | Gynecologic Oncology Group | 2500 | 2007-09-01 | 2018-05-22 | |
| Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Laboratory Biomarker Analysis - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 1873 | 2005-09-01 | 2019-07-23 |
Showing 20 of 23. Sign in to see all of them.
Ovarian Neoplasms (23) · Fallopian Tube Neoplasms (14) · Breast Neoplasms (6) · Brenner Tumor (5) · Carcinoma, Renal Cell (4) · Melanoma (4) · Carcinoma, Non-Small-Cell Lung (3) · Stomach Neoplasms (3) · Urinary Bladder Neoplasms (3) · Uterine Cervical Neoplasms (3) · Astrocytoma (2) · Brain Neoplasms (2) · Carcinoma, Hepatocellular (2) · Colonic Neoplasms (2) · Esophageal Neoplasms (2)
Adnexal Diseases (23) · Endocrine Gland Neoplasms (23) · Endocrine System Diseases (23) · Female Urogenital Diseases (23) · Female Urogenital Diseases and Pregnancy Complications (23) · Genital Diseases (23) · Genital Diseases, Female (23) · Genital Neoplasms, Female (23) · Gonadal Disorders (23) · Neoplasms (23) · Neoplasms by Site (23) · Ovarian Diseases (23) · Urogenital Diseases (23) · Urogenital Neoplasms (23) · Fallopian Tube Diseases (14)
Carboplatin (4) · Paclitaxel (3) · Sirolimus (3) · Taxes (3) · Bevacizumab (2) · Disulfides (2) · Immunoglobulin G (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · 4-(3-fluoropropyl)glutamic acid (1) · Aprepitant (1) · Calcium Dobesilate (1) · Chemotherapy, Adjuvant (1) · Cisplatin (1) · Colony-Stimulating Factors (1)
Gynecologic Oncology Group (7) · National Cancer Institute (NCI) (4) · Roswell Park Cancer Institute (3) · Mayo Clinic (2) · University of Washington (2) · Alliance for Clinical Trials in Oncology (1) · Barbara Ann Karmanos Cancer Institute (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · Stanford University (1) · Vanderbilt-Ingram Cancer Center (1)
United States (19) · Canada (3) · Japan (1) · South Korea (1)
Kunle Odunsi (2) · Andrea Barsevick, PhD (1) · Charles Loprinzi (1) · Daniel Renouf (1) · David Gershenson (1) · Emese Zsiros, MD (1) · Frances Lewis (1) · George Coukos (1) · Henry Pitot (1) · John Liao (1) · Katherine Bell-McGuinn (1) · Lawrence Lum (1) · Lisa Hess (1) · Manali Patel (1) · Marta Crispens, MD (1)
PMID 21941283, PMID 22204724, PMID 23219660, PMID 25318437, PMID 25488966, PMID 26487588, PMID 29550184, PMID 31216226, PMID 31653510, PMID 34749008, PMID 35144591, PMID 35771552, PMID 36252167, PMID 37185961, PMID 37702588, PMID 40132910
U10CA027469 (4), U10CA180868 (4), P30CA015083 (2), P30CA015704 (2), P30CA016056 (2), R01CA158318 (2), U10CA101165 (2), N01CM00032 (1), N01CM00038 (1), N01CM00039 (1), N01CM00070 (1), N01CM00071 (1), N01CM00099 (1), N01CM00100 (1), N01CM62201 (1)